SciELO - Scientific Electronic Library Online

vol.135 número5Identificación molecular de enzimas modificantes de aminoglucósidos en cepas de Enterococcus spp. aisladas en hospitales de la Octava Región de ChileCambios en la prevalencia de asma en escolares chilenos entre 1994 y 2002: International Study of Asthma and Allergies in Childhood (ISAAC) - Chile phases I and III índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados


Revista médica de Chile

versão impressa ISSN 0034-9887


RUIZ B, Carolina et al. Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients. Rev. méd. Chile [online]. 2007, vol.135, n.5, pp.573-579. ISSN 0034-9887.

Background: Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective. Aim: To report the experience in our Health Centre with rapamycin-eluting stents. Patients and methods: Forty two stents with rapamicine were implanted to 32 diabetic patients, between June 2002 and December 2004. After the procedure, subjects were clinically followed-up for an average period of 19.9+9.9 months, evaluating functional capacity, angina pectoris, dyspnea, need for hospital admission, acute coronary events and cardiac death. In those subjects clinically suspected to have restenosis, a coronary angiography was performed. Results: Twenty-nine subjects (90.6%) remained asymptomatic, two subjects (6.3%) developed angina pectoris but restenosis was ruled out, and one subject (3.1%) died. Conclusions: The use of rapamycin-eluting stents in these patients was safe and successful with no evidence of clinic restenosis. These positive results are similar to those reported in the Diabetes Study

Palavras-chave : Angioplasty; Sirolimus; Stents.

        · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons